Computationally repurposing drugs for breast cancer subtypes using a network-based approach

BMC Bioinformatics

Table 9 Top 20 drugs corresponding to subtype 8

Rank	Drug	Dosage (μm)	Treatment time (h)	Score	Drug type	References
1	Semaxanib	0.04	24	− 0.6	Investigational	[79]
2	Ruxolitinib	10	24	− 0.56	Approved	[51, 52]
3	Goserelin-Acetate	0.04	24	− 0.55	Approved	[81]
4	Raloxifene	0.04	24	− 0.54	Approved	[99]
5	XMD11-85h	0.04	3	− 0.49	Experimental
6	Deferiprone	0.04	24	− 0.49	Approved	[66, 67]
7	Cinepazide	0.04	24	− 0.48	Investigational
8	Ebselen	10	24	− 0.48	Investigational	[100]
9	WH-4-025	0.04	24	− 0.48	Experimental
10	Nimesulide	0.04	24	− 0.47	Approved	[112]
11	Rupatadine	0.04	24	− 0.47	Approved
12	Phentermine	0.04	24	− 0.47	Approved
13	MF-101	10	24	− 0.47	Experimental
14	Amiprilose	0.04	24	− 0.47	Experimental
15	Etofylline-Clofibrate	10	24	− 0.47	Approved
16	XMD-1150	10	3	− 0.46	Experimental
17	Lidocaine	10	24	− 0.46	Approved	[86, 87]
18	TG-100801	0.04	24	− 0.46	Investigational
19	Dasatinib	10	24	− 0.45	Approved	[101]
20	Apitolisib	10	24	− 0.45	Investigational	[113]

ISSN: 1471-2105